MapLight Therapeutics, Inc. MPLT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $172.25M— | $138.35M— | $94.44M— | $84.16M— | —— | ||
| $37.8M— | $30.73M— | $14.04M— | $13.72M— | —— | ||
| $210.04M— | $169.08M— | $108.48M— | $97.88M— | —— | ||
| $210.04M— | $169.08M— | $108.48M— | $97.88M— | —— | ||
| -$210.04M— | -$169.08M— | -$108.48M— | -$97.88M— | —— | ||
| $7.18M— | $5.52M— | $3.95M— | $3.48M— | —— | ||
| $8.9M— | $7.93M— | $5.65M— | $5.45M— | —— | ||
| -$199.48M-146% | -$161.15M-108% | -$102.83M— | -$92.43M— | -$80.99M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$200.45M— | -$161.54M— | -$103.21M— | -$92.2M— | —— | ||
| -$969K— | -$392K— | —— | —— | —— | ||
| $3.38M— | $2.41M— | $1.7M— | $1.97M— | —— | ||
| -$210.04M— | -$169.08M— | -$108.48M— | -$97.88M— | —— | ||
| -$209.47M— | -$168.51M— | -$107.85M— | -$97.15M— | —— | ||
| -$209.47M— | -$168.51M— | -$107.85M— | -$97.15M— | —— | ||
| -$210.04M— | -$169.08M— | -$108.48M— | -$97.88M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MapLight Therapeutics, Inc. profitable?
- MapLight Therapeutics, Inc. is not currently profitable: it reported a net loss of $199.5M over the trailing twelve months.
- What is MapLight Therapeutics, Inc. 's earnings per share?
- MapLight Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-95.86.
- Where does MapLight Therapeutics, Inc. 's income statement data come from?
- Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.